Related coverage linked through entity extraction aliases.
May 25, 2026
A study links sugary drink consumption to anxiety in adolescents, while separate research shows parental substance use patterns strongly influence teen consumption, with authoritative parenting styles offering protective effects.
May 21, 2026
Tent5a was identified as a positive regulator of insulin production in pancreatic beta cells. Overexpression extended poly(A) tails of insulin transcripts and increased insulin content.
May 18, 2026
Wegovy and Mounjaro prices in South Korea are higher than in China and Japan. South Korea added both drugs to a non-insurance reporting system, but immediate price cuts are unlikely.
May 17, 2026
Pfizer is running a Phase 1 open-label multiple-dose study of PF-08653944 in adults with overweight or obesity. The study will assess gastric emptying and safety, with an update filed on 20 April 2026.
May 14, 2026
Lilly said a Phase IIIb trial of ixekizumab plus tirzepatide in psoriasis and obesity or overweight beat ixekizumab alone on complete skin clearance plus at least 10% weight loss at 36 weeks.
May 13, 2026
A review of more than 200 studies linked up to a third of dementia cases to diseases outside the brain. Trials and broader evidence also support multi-domain prevention strategies.
May 13, 2026
Eli Lilly reported positive phase 3b Together-PsO results for Taltz plus Zepbound in adults with plaque psoriasis and obesity or overweight. Separate meeting updates highlighted new oral plaque psoriasis therapies with biologic-like efficacy.
May 12, 2026
Rhythm reported Q1 2026 IMCIVREE revenue of $60.1 million and said more than 150 patient start forms were received after U.S. approval in acquired hypothalamic obesity. The company also cited European authorization and a Japanese application under review.
May 12, 2026
Trump secured agreements with 16 pharmaceutical companies tied to TrumpRx.gov, including most-favoured-nation pricing and direct-to-patient discounts. Several companies disclosed price cuts for obesity, diabetes, insulin and other medicines.
May 05, 2026
Alnylam reported full-year 2025 profitability and $2.987 billion in global net product revenues, driven by U.S. approval and growth of AMVUTTRA. The company also outlined 2026 pipeline goals and additional HELIOS-B analyses for vutrisiran.
May 04, 2026
GLP-1 drugs used for type 2 diabetes and obesity are seeing rising demand for weight loss as safety concerns also draw attention. A 2025 WHO guideline said long-term safety data remains limited.
May 02, 2026
Vermont insurers and employers are scaling back GLP-1 coverage as costs rise, leaving some patients without access. The drugs remain in high demand as studies point to benefits beyond weight loss.
May 02, 2026
Pfizer reported new clinical and regulatory milestones across oncology, obesity and hemophilia, including BREAKWATER Phase 3 data and Priority Review for HYMPAVZI. The company also cited MagnetisMM-5 results and FDA priority review for PADCEV.
Apr 26, 2026
Morphic Medical’s Reset obesity treatment device received NUB status in Germany, allowing hospitals to seek supplementary reimbursement. The company said U.S. FDA study enrollment is continuing after protocol changes to accelerate recruitment.
Apr 25, 2026
A study in Ophthalmology found tirzepatide use was associated with lower 12-month risk of new or progressive diabetic retinopathy versus lifestyle intervention alone. The analysis included about 174,000 matched patients.
Apr 23, 2026
January and March 2026 drug pipeline updates included Phase 3 results, Fast Track designations and Priority Review decisions across multiple disease areas. Mavacamten, teplizumab-mzwv, anifrolumab, AXS-05, gedatolisib and AFTX-201 were among the programs with notable milestones.
Apr 23, 2026
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
Apr 22, 2026
Adial Pharmaceuticals completed demonstration batch production for AD04, meeting prespecified specifications and matching the prior Phase 2 dissolution profile. The step enables clinical and registration batch production for the planned Phase 3 trial.
Apr 20, 2026
UAB researchers are advancing cancer prevention, tumor targeting and precision ablation, while AdvanCell is developing targeted alpha therapy and a prostate cancer drug in Phase 1 trials. Both efforts focus on new treatment approaches and research infrastructure.
Apr 19, 2026
Biopharma companies face a $275b patent cliff as licensing activity shifts toward China. China represented almost half of 2025 licensing activity and contributes about 30% of the global biotech pipeline.
